Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Chloe Cote, Mael Heiblig, Urbain Tauveron-Jalenques, Martin Carre, Amine Belhabri, Gaspar Aspas Requena, Sylvain Lamure, Ugo Thévenet, Clemence Santana, Adrien Contejean, Jerome Cornillon, Elisabeth Daguenet, Pascale Flandrin-Gresta, Emmanuelle Tavernier

Blood (2025) 146 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2025-3442

Published: 2025

Journal Articles

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Blood (2025) 146 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2025-3398

Published: 2025

Journal Articles

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Mathilde Chanut, Imane Belhadi, Emmanuel Raffoux, Juliette Soret, Geoffroy Venton, Vincent Alcazer, Lenaig Le Clech, Jean-Christophe Ianotto, Mathieu Meunier, Paul Denous Chataigner, Mathilde Hunault, Ugo Thévenet, Elsa Lestang, Antoine Bonnet, Rafael Daltro De Oliveira, Ahmad Aljijakli, Florence Sabirou, Lina Benajiba, Jean-Jacques Kiladjian

Blood (2025) 146 (Supplement 1): 7316.

https://doi.org/10.1182/blood-2025-7316

Published: 2025

Journal Articles

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Emmanuelle Tavernier, Jérôme Cornillon, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carré, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2024-203496

Published: 2024

Journal Articles

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Adrien Contejean, Pierre Chauvelot, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Clémence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Gian Matteo Pica, Arthur Dony, Amine Belhabri, Mauricette Michallet, Zofia Gross, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2024-207605

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Adrien Contejean, Clemence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Pica Gian-Matteo, Dony Arthur, Amine Belhabri, Mauricette Michallet, Pedro Chorao, Mael Heiblig, Gaspar Aspas Requena

Blood (2024) 144 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2024-208577

Published: 2024

Journal Articles

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Mael Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Martin Carre, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Zofia Gross

Blood (2024) 144 (Supplement 1): 846.

https://doi.org/10.1182/blood-2024-207764

Published: 2024

Journal Articles

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carre, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2024-208817

Published: 2024

Journal Articles

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

Yann Guillermin, Stéphane Morisset, Ugo Thévenet, Emmanuelle Nicolas-Virelizier, Anne-Sophie Michallet, Jerome Cornillon, Manon Sapet, Valentin Daguerre, Emmanuel Beillard, Denis Guyotat, Elisabeth Daguenet, Ludovic Fouillet

Blood (2023) 142 (Supplement 1): 129.

https://doi.org/10.1182/blood-2023-180601

Published: 2023

Journal Articles

A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma

Valentin Daguerre, Elisabeth Daguenet, Nicolas Jacquet-Francillon, Ludovic Fouillet, Ugo Thévenet, Maxime Bonjour, Herve Ghesquieres, Imran Ahmad, Jerome Cornillon

Blood (2023) 142 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2023-181710

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Spplaash Study: A Randomized Study to Evaluate the Incidence of Postdural Puncture Headache with the Use of Atraumatic Needles in Hematology

A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only